A detailed history of Rafferty Asset Management, LLC transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 220,794 shares of MORF stock, worth $7.52 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
220,794
Previous 202,726 8.91%
Holding current value
$7.52 Million
Previous $5.85 Million 32.75%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$26.64 - $40.31 $481,331 - $728,321
18,068 Added 8.91%
220,794 $7.77 Million
Q4 2023

Feb 13, 2024

BUY
$19.95 - $31.0 $1.27 Million - $1.97 Million
63,634 Added 45.75%
202,726 $5.85 Million
Q3 2023

Nov 13, 2023

BUY
$21.33 - $59.42 $192,247 - $535,552
9,013 Added 6.93%
139,092 $3.19 Million
Q2 2023

Aug 11, 2023

BUY
$34.33 - $62.11 $2.45 Million - $4.43 Million
71,298 Added 121.29%
130,079 $7.46 Million
Q1 2023

May 11, 2023

SELL
$26.01 - $48.69 $1.32 Million - $2.47 Million
-50,777 Reduced 46.35%
58,781 $2.21 Million
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $369,583 - $464,964
15,310 Added 16.24%
109,558 $2.93 Million
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $299,193 - $449,126
13,459 Added 16.66%
94,248 $2.67 Million
Q2 2022

Aug 12, 2022

BUY
$19.74 - $43.01 $259,186 - $564,721
13,130 Added 19.41%
80,789 $1.75 Million
Q1 2022

May 13, 2022

BUY
$36.25 - $52.02 $499,053 - $716,159
13,767 Added 25.55%
67,659 $2.72 Million
Q4 2021

Feb 10, 2022

BUY
$43.27 - $65.72 $1.07 Million - $1.62 Million
24,703 Added 84.63%
53,892 $2.55 Million
Q3 2021

Nov 10, 2021

BUY
$53.61 - $67.5 $1,286 - $1,620
24 Added 0.08%
29,189 $1.65 Million
Q2 2021

Aug 10, 2021

BUY
$45.13 - $64.99 $1.32 Million - $1.9 Million
29,165 New
29,165 $1.67 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.